Detalhe da pesquisa
1.
Conformational control of Cas9 by CRISPR hybrid RNA-DNA guides mitigates off-target activity in T cells.
Mol Cell
; 81(17): 3637-3649.e5, 2021 09 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34478654
2.
Generation of a Commercial-Scale Founder Population of Porcine Reproductive and Respiratory Syndrome Virus Resistant Pigs Using CRISPR-Cas.
CRISPR J
; 7(1): 12-28, 2024 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38353617
3.
High-Specificity CRISPR-Mediated Genome Engineering in Anti-BCMA Allogeneic CAR T Cells Suppresses Allograft Rejection in Preclinical Models.
Cancer Immunol Res
; 12(4): 462-477, 2024 Apr 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38345397
4.
Harnessing type I CRISPR-Cas systems for genome engineering in human cells.
Nat Biotechnol
; 37(12): 1471-1477, 2019 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31740839
5.
The synthetic histone-binding regulator protein PcTF activates interferon genes in breast cancer cells.
BMC Syst Biol
; 12(1): 83, 2018 09 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-30253781
6.
Regulation of cancer epigenomes with a histone-binding synthetic transcription factor.
NPJ Genom Med
; 22017.
Artigo
em Inglês
| MEDLINE | ID: mdl-28919981
7.
Erratum: Regulation of cancer epigenomes with a histonebinding synthetic transcription factor.
NPJ Genom Med
; 2: 27, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-29263837